KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Common Equity (2016 - 2025)

Historic Common Equity for Jazz Pharmaceuticals (JAZZ) over the last 17 years, with Q3 2025 value amounting to $4.0 billion.

  • Jazz Pharmaceuticals' Common Equity fell 508.35% to $4.0 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $4.0 billion, marking a year-over-year decrease of 508.35%. This contributed to the annual value of $4.1 billion for FY2024, which is 954.67% up from last year.
  • Per Jazz Pharmaceuticals' latest filing, its Common Equity stood at $4.0 billion for Q3 2025, which was down 508.35% from $3.7 billion recorded in Q2 2025.
  • Jazz Pharmaceuticals' Common Equity's 5-year high stood at $4.2 billion during Q1 2025, with a 5-year trough of $2.7 billion in Q3 2022.
  • Over the past 5 years, Jazz Pharmaceuticals' median Common Equity value was $3.7 billion (recorded in 2023), while the average stood at $3.7 billion.
  • As far as peak fluctuations go, Jazz Pharmaceuticals' Common Equity soared by 3522.13% in 2021, and later crashed by 3029.81% in 2022.
  • Jazz Pharmaceuticals' Common Equity (Quarter) stood at $4.0 billion in 2021, then decreased by 22.18% to $3.1 billion in 2022, then rose by 21.11% to $3.7 billion in 2023, then grew by 9.55% to $4.1 billion in 2024, then dropped by 3.29% to $4.0 billion in 2025.
  • Its Common Equity stands at $4.0 billion for Q3 2025, versus $3.7 billion for Q2 2025 and $4.2 billion for Q1 2025.